Search Results

Precision BioSciences, Inc. today announced its addition to the Russell Microcap® Index.

Precision BioSciences, Inc. today announced that members of management will participate in the following upcoming investor conferences in June.

Precision BioSciences, Inc. (Nasdaq: DTIL) today announced that it will publish financial results for the first quarter 2024 and provide a business update on Monday, May 13, 2024.

Precision BioSciences, Inc. today announced that, on May 13, 2024, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees.

Precision BioSciences, Inc. is presenting data today at the United Mitochondrial Disease Foundation’s (UMDF) Mitochondrial Medicine 2024 Conference being held in Cleveland, Ohio from June 26-29, 2024.

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.

Precision BioSciences, Inc. (Nasdaq: DTIL) today announced that it had granted Caribou Biosciences, Inc., a leading CRISPR genome-editing cell therapy company, a non-exclusive, worldwide license, with the right to sublicense, to one of Precision’s foundational cell therapy patent families for use with CRISPR in the field of human therapeutics.

Precision BioSciences, Inc. today announced that it has entered into a definitive subscription agreement, pursuant to which the Company will issue and sell in a non-brokered private placement to members of its senior leadership team.

Precision BioSciences, Inc. today announced that the company will present preclinical data for its PBGENE-HBV clinical candidate at the European Association for the Study of the Liver Congress (EASL), highlighting the differentiated ability of ARCUS to make efficient, durable, and targeted elimination edits.

Precision BioSciences, Inc., an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, announced financial results for the first quarter ended March 31, 2024, and provided a business update.